Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients
Association of PAX4 genetic variants with oral antidiabetic drugs efficacy in Chinese type 2 diabetes patients
复制标题
中国2型糖尿病患者PAX4基因变异与口服降糖药疗效的关系
DOI：
10.1038/tpj.2014.18
复制
发表时间：
2014-10-01
影响因子：
2.8
通讯作者：
Jia, W.
中科院分区：
文献类型：
--
作者：
Chen, M.;Hu, C.;Jia, W.
本研究的目的是探讨 PAX4 变异与中国 2 型糖尿病 (T2DM) 患者口服降糖药物治疗效果的关系。共有209名新诊断的T2DM患者被随机分配接受瑞格列奈或罗格列酮治疗48周，并比较治疗效果。在罗格列酮队列中，与 GG 纯合子相比，rs6467136 GA+ AA 携带者的 2 小时血糖水平下降幅度更大（P = 0.0063），并且目标 2 小时血糖水平的累积达到率更高（P logrank = 0.0093）。在β细胞功能缺陷的亚组中，rs6467136 GA+ AA携带者表现出更大的2小时血糖水平下降和胰岛素抵抗稳态模型评估的改善（P = 0.0143）。此外，GA+ AA 携带者更有可能达到目标空腹和 2 小时血糖水平（P log 等级分别 = 0.0091 和 0.007）。然而，这些单核苷酸多态性对瑞格列奈疗效没有影响。总之，PAX4变异rs6467136与罗格列酮对中国T2DM患者的治疗效果相关。
The aim of this study was to investigate the association of PAX4 variants with therapeutic effect of oral antidiabetic drugs in Chinese type 2 diabtes mellitus (T2DM) patients. A total of 209 newly diagnosed T2DM patients were randomly assigned to treatment with repaglinide or rosiglitazone for 48 weeks, and the therapeutic effects were compared. In the rosiglitazone cohort, rs6467136 GA+ AA carriers showed greater decrease in 2-h glucose levels (P= 0.0063) and higher cumulative attainment rates of target 2-h glucose levels (P log rank= 0.0093) than GG homozygotes. In the subgroup with defective β-cell function, rs6467136 GA+ AA carriers exhibited greater decrements of 2-h glucose level and improvement of homeostasis model assessment of insulin resistance (P= 0.0143). Moreover, GA+ AA carriers were more likely to attain the target fasting and 2-h glucose level (P log rank= 0.0091 and 0.007, respectively). However, these single-nucleotide polymorphisms showed no effect on repaglinide efficacy. In conclusion, PAX4 variant rs6467136 was associated with the therapeutic effect of rosiglitazone in Chinese T2DM patients.